-

Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021 at 12:10 p.m. ET.

About Autobahn Therapeutics
Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist for the treatment of adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com

Industry:

Autobahn Therapeutics

Release Versions
English

Contacts

Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today reported new nonclinical data on the antidepressant mechanism of action for elunetirom, its lead investigational therapy in Phase 2 development for adjunctive treatment of bipolar depression and major depressive disorder (MDD). The data show that elunetirom rapidly increased the number of synaptic connections between neurons...

Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced positive topline data from its Phase 2 AMPLIFY-BD trial evaluating elunetirom as an adjunctive treatment in patients with bipolar I or bipolar II depression, a disorder affecting approximately 7 million adults in the U.S. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, ac...

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that management will participate in the following upcoming investor conferences in June. 2026 Jefferies Global Healthcare Conference Investor Meetings: Tuesday, June 2, 2026 Location: New York, NY 2026 UBS Virtual CNS Day Fireside Chat and Investor Meetings: Monday, June 15, 2026 Location: Virtual About Autobahn The...
Back to Newsroom